Due diligence and new therapeutic areas

Faster safety decisions on new assets and new indications

Whether you are assessing an asset to acquire or taking one you already have into a new therapeutic area, the first questions are the same: what is known about its safety, what the comparators show, and what is missing. Timelines are usually very tight. Metisox gives your team an expert-reviewed answer in days rather than weeks, while you keep the lead and the decision.

Discuss your due diligence

Who we are

For over two decades we have built a proprietary, expertly curated knowledge base, with more than 200 person-years of curation, linking chemicals, therapeutic modalities, genes, proteins, diseases, phenotypes and adverse outcomes. The same database underpins EU research consortia such as PrecisionTox and SYSCILIA. Most of the top 20 global pharma companies work with us.

What makes the network unique

Evidence that sits in no single paper

Our knowledge base combines open and proprietary data, curated by experts and linked into one network of scored relationships. Because everything is connected, the network finds information that no publication states on its own.

Where there is no direct evidence, the network traces what sits one or two nodes away: an interaction partner, a shared pathway, a structurally similar compound. It shows the route as well as the conclusion, and keeps direct evidence separate from network inference.

A missing reference can look exactly like an absence of evidence, and on an asset decision that is the expensive mistake.

Your query

Chemical structure

Structure search

Protein name or sequence

Protein target search

Observed toxicity as text

Text search engine, e.g. liver necrosis

Dysregulated genes

Genomics, proteomics, metabolomics

SysWiz

SysWiz knowledge base

6.5M scored relationships

SysWiz software

What comes back

Mechanistic hypothesis

Affected pathway

Toxicity profiles

Species differences

20+years of curation

6.5M+scored relationships

~20khuman genes and proteins

1M+small molecules

80k+biologics, antibodies, siRNA

Our software finds the evidence. Our experts weigh it. Your team makes the call.

From a new asset to a new indication

Assessing an asset to acquire and taking one into a new therapeutic area start with the same need: a quick, reliable view of the evidence, without searching publications by hand.

Due diligence on a new asset

What you send

A compound name, a structure or a target is enough to start. Study reports or clinical packages make the answer more focused.

We work under NDA. Your data is used only for your project and never for other clients.

What we screen

Toxicology and translational safety, cardiovascular liabilities, in silico secondary pharmacology and off-target panels, and species differences. Comparators and same-class compounds, public data and clinical trials. Small molecules, biologics and oligonucleotides.

What comes back

Within about 48 hours, a few slides prepared by our experts: the main safety signals, the strength of evidence behind each, and where information is lacking.

First pass

about 48 hours

Deep dive

a metabolite, neurotoxicity

Full assessment

as data comes in

The question can start broad and change direction. The same project follows it.

Example. An effect seen in rats was linked to a metabolite. Our weight of evidence showed the metabolite does not form in humans, and the argument went into the response to the FDA.

A new therapeutic area or indication

What you send

An asset name, a structure or a target. Optionally the current indication, the mechanism of action and any internal data.

What we screen

Safety of the mechanism of action in the new disease and patient population, the clinical trial landscape and comparators in that area, and links from human genetics and phenotypes.

What comes back

A short report prepared by our experts: where the mechanism fits, where it raises safety concerns, and where evidence is missing.

For clinical pharmacology and analytics teams

New indications and novel mechanisms

Beyond safety, the network links a mechanism of action to diseases, pathways and phenotypes. It generates hypotheses on where an asset could work, and on mechanisms not yet described, with the evidence path behind each.

Biomarkers and patient stratification

We identify biomarkers and stratify patients from clinical and omics data, including after launch, to find the patients who respond best and extend the value of an existing asset.

Example. An investor asked which indications a late-stage asset could fit, based on the clinical trial landscape. We identified candidate indications outside their existing portfolio.

What your team can decide with it

Walk away early

Stop before more time goes into an asset with a serious liability.

Negotiate on price

Use documented gaps and open risks in the negotiation.

Request the right data

Ask for the studies that close the gaps we flag.

Focus your review

Put your team's time on the questions that matter most.

Pick the indication

Where the mechanism fits and the risks are known.

Across the pipeline

From target discovery to post approval, with due diligence support at any point in the cycle.

DiscoveryDevelopmentCommercialization

Target discoveryHit generationLead identificationLead optimizationAnimal modelsClinical trialsFDA/EMA reviewManufacturingPost approval

Due diligence support: at any stage, from early targets to marketed products

Target safety assessment (TSA): express reports

Automated TSA reports

Multi-target TSA reports

Full TSA reports

Patient stratification and biomarker discovery

Carcinogenicity risk assessment: ICH S1B(R1)

Developmental and reproductive toxicity: ICH S5(R3)

New indications: the mechanism in a new disease

Off-target effects report

Post-marketing biomarkers for disease progression

Expert reports AI/ML automated reports

Use our software, our experts, or both

Our experts

A second opinion tailored to your question: slides for a first pass, a full report when needed, in your own format.

Our software

Licensed access to our curated database and software, including the Target Assessment Report (TAR) platform for automated target safety assessments.

Both

The most common pattern: your team explores on its own, and our experts step in when diligences overlap.

Why you can rely on it

Experts review every assessment: registered toxicologists and molecular biologists, matched to the question.
Scored and traceable: every relationship carries a confidence level and its publications.
Output and interpretation kept apart: direct evidence separate from network inference.
Gaps flagged, not hidden: absence of evidence is not evidence of absence.

How we work together

A pilot on a real case
Time-boxed: a first pass on an asset under due diligence, or an existing asset in a new indication.
Review together, then decide
What matched your view, what we found that you had not.
Ongoing collaboration
First passes when diligences overlap, deep dives when a question narrows.

An expert-reviewed answer in days, not weeks.

Start with a time-boxed pilot on a real case: a first pass on an asset under due diligence, or an existing asset in a new indication.

Discuss your due diligence